topotecan has been researched along with Innate Inflammatory Response in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kao, G; Xiao, J; Xu, Y; Yan, M; Zhang, Y; Zhou, K | 1 |
| Gan, J; Gao, Y; Guo, S; Ning, S; Sun, Y; Wang, P; Wang, X; Xiao, Y; Zhang, Y; Zhi, H; Zhou, H | 1 |
| Albrecht, RA; Aydillo, T; Bakker, J; Balasuriya, UBR; Benner, C; Byun, M; Campisi, L; Carossino, M; Chanda, SK; Chen, H; Escalera, A; Fstkchyan, YS; Garcia-Sastre, A; Gaudreault, NN; Guccione, E; Heinz, S; Ho, JSY; Indran, SV; Jangra, S; Jeyasekharan, AD; Jordan, T; Kaufman, DA; Lau, SY; Lee, AC; Liu, H; Liu, WC; Malysheva, V; Marazzi, I; Meekins, DA; Melo, BS; Miraldi, ER; Mok, BW; Moreira, AL; Morozov, I; Parameswaran, S; Rathnasinghe, R; Ray-Jones, H; Richt, JA; Schotsaert, M; Sebra, R; Shum, E; Spivakov, M; TenOever, BR; Thiecke, MJ; Trujillo, JD; Wayman, JA; Weirauch, MT; White, K; Yildiz, S; Zhang, AJ; Zhao, N; Zheng, S; Zhu, Z | 1 |
| Chen, MZ; Hu, YB; Jin, JJ; Liu, HB; Lv, TF; Song, Y; Wan, B; Wang, XX; Xi, GM; Xu, WJ; Zhan, P; Zhang, XW; Zhu, SH | 1 |
| Basler, C; Benner, C; Bouvier, N; Bukreyev, A; Campisi, L; Chen, X; Edwards, M; Fenouil, R; García-Sastre, A; Heinz, S; Ho, JSY; Jin, J; Jordan, S; Lagda, AC; Marazzi, I; Martinez-Gil, L; Merad, M; Metreveli, G; Munoz-Fontela, C; Peralta, Z; Pietzsch, C; Rialdi, A; van Bakel, H; Weirauch, M; Zhao, N | 1 |
5 other study(ies) available for topotecan and Innate Inflammatory Response
| Article | Year |
|---|---|
Hypoxia-inducible transcription factor-1α inhibition by topotecan protects against lipopolysaccharide-induced inflammation and apoptosis of cardiomyocytes.
Topics: Apoptosis; Humans; Hypoxia; Inflammation; Lipopolysaccharides; Myocytes, Cardiac; Topotecan; Transcription Factors | 2021 |
PD-L1-Mediated Immunosuppression in Hepatocellular Carcinoma: Relationship with Macrophages Infiltration and Inflammatory Response Activity.
Topics: B7-H1 Antigen; Carcinoma, Hepatocellular; Cytokines; Dasatinib; Humans; Immunosuppression Therapy; Inflammation; Liver Neoplasms; Macrophages; Programmed Cell Death 1 Receptor; Topotecan; Tumor Microenvironment; Vemurafenib | 2022 |
TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation.
Topics: Animals; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; DNA Topoisomerases, Type I; Humans; Inflammation; Mesocricetus; Mice; Mice, Transgenic; SARS-CoV-2; THP-1 Cells; Topoisomerase I Inhibitors; Topotecan; Vero Cells | 2021 |
Topotecan alleviates ventilator-induced lung injury via NF-κB pathway inhibition.
Topics: Acute Lung Injury; Animals; Apoptosis; Bronchoalveolar Lavage Fluid; Caspase 3; Cytokines; Disease Models, Animal; Epithelial Cells; Inflammation; Lung; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Peroxidase; Topotecan; Ventilator-Induced Lung Injury | 2018 |
Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation.
Topics: Animals; Azepines; Camptothecin; DNA Topoisomerases, Type I; Ebolavirus; Flavonoids; Gene Expression Regulation; HEK293 Cells; Hemorrhagic Fever, Ebola; Host-Pathogen Interactions; Humans; Immunity, Innate; Inflammation; Influenza A virus; Interferon-beta; Mice; Mice, Inbred C57BL; Piperidines; Positive Transcriptional Elongation Factor B; RNA Polymerase II; Sendai virus; Staphylococcal Infections; Staphylococcus aureus; Topoisomerase I Inhibitors; Topotecan; Transcription, Genetic; Triazoles | 2016 |